TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given his Buy rating due to a combination of factors surrounding Benitec Biopharma’s financial and clinical progress. The company has a strong cash position of $98 million, which is projected to sustain operations through 2027. This financial stability supports the ongoing Phase 1b/2a trial and the anticipated start of a registrational trial in the second half of 2026.
Additionally, the company’s investigational therapy, BB-301, is advancing in its clinical trials for OPMD dysphagia, with promising interim data expected in the fourth quarter of 2025. The study involves both objective and subjective measures, which will provide comprehensive insights into the therapy’s efficacy. These factors, combined with strategic financial management and promising clinical data, underpin the Buy rating recommendation.
In another report released today, Citizens JMP also reiterated a Buy rating on the stock with a $20.00 price target.